Skip to main navigation
Skip to content
Opiant_logo Opiant
Main Menu
  • Contact
  • Careers
  • About
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
    • Media
    • Careers
      • Culture at Opiant
  • Science & Technology
    • The Science of Addiction
    • Opioid Antagonists
    • Nasal Spray Delivery Technology
    • Antagonist for Acute Cannabinoid Overdose
    • Intellectual Property
    • Publications
  • Addiction Disorders
    • Overview
    • Opioid Use Disorder
    • Alcohol Use Disorder
    • Cannabinoid Use Disorder
  • Products & Pipeline
  • Patients & Families
    • Overview
    • Clinical Trials
    • External Resources
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Financials & Filings
      • SEC Filings
      • Annual Reports & Proxy Statements
    • Investor Resources
      • Information Request
      • Contact IR
      • Email Alerts

Investors

Annual Reports & Proxy Statements

Annual Reports & Proxy Statements

Annual Reports
2016 Annual Report
2015 Proxy Statement
2015 Annual Report
2014 Annual Report
2014 Proxy Statement
2013 Proxy Statement
2013 Annual Report
2012 Annual Report
2011 Annual Report
Quarterly & Other Reports
Q1 2017 10-Q
December 15, 2016
Q3 2016 10-Q
June 8, 2016
Q2 2016 10-Q
March 15, 2016
Print Page
RSS Feeds
Email Alerts
Contact IR

  • Privacy Policy
  • Site Map
© Opiant, 2019. All Rights Reserved.